SECTION 1. IDENTIFICATION

Product name : Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
          Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Combustible dust

Eye irritation : Category 2A
Respiratory sensitization : Category 1
Reproductive toxicity : Category 2
Specific target organ systemic toxicity - repeated exposure : Category 2 (Kidney)

GHS label elements
Hazard pictograms :

Signal Word : Danger
Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air. H319 Causes serious eye irritation. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Kidney) through prolonged or repeated exposure.

Precautionary Statements : Prevention:
P201 Obtain special instructions before use.
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 8.0  Revision Date: 04/24/2019  SDS Number: 67748-00015  Date of last issue: 02/07/2019  Date of first issue: 02/27/2015

P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P285 In case of inadequate ventilation wear respiratory protection.

Response:
P304 + P341 IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 IF eye irritation persists: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact:
In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact:
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed:
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.

Notes to physician:
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)

Unsuitable extinguishing media:
None known.

Specific hazards during fire fighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides
Metal oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-
tion

SECTION 6. ACCIDENTAL RELEASE MEASURES

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitized individuals should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers.
Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium hydrogen [R-[R*,S*- (Z)]]-7-[(2-amino-2-carboxylatoethyl)thio]-2-[[2,2-dimethylcyclopropyl]carbonyl]amino]hept-2-enoate</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>TWA</td>
<td>0.3 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: RSEN

Engineering measures:
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection:
General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection:
Material: Chemical-resistant gloves

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a
Skin and body protection: Work uniform or laboratory coat.

Hygiene measures:
- Ensure that eye flushing systems and safety showers are located close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance**: powder
- **Color**: No data available
- **Odor**: No data available
- **Odor Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapor pressure**: No data available
- **Relative vapor density**: No data available
- **Relative density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
- **Partition coefficient: n-octanol/water**: No data available
SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Acute oral toxicity: LD50 (Rat): > 10,000 mg/kg
LD50 (Mouse): > 10,000 mg/kg

Imipenem:
Acute oral toxicity: LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration):
LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous
LD50 (Mouse): 1,500 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:
Sodium hydrogen [R-[R*,S*--(Z)]]-7-[(2-amino-2-carboxyloctylthio)-2-[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate:
Species: Rabbit
Result: No skin irritation

Relebactam:
Method: EpiDerm
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:
Sodium hydrogen [R-[R*,S*--(Z)]]-7-[(2-amino-2-carboxyloctylthio)-2-[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate:
Species: Rabbit
Result: Moderate eye irritation

Relebactam:
Result: No eye irritation
Method: Bovine cornea (BCOP)

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:
Sodium hydrogen [R-[R*,S*--(Z)]]-7-[(2-amino-2-carboxyloctylthio)-2-[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate:
Routes of exposure: Skin contact
Remarks: No data available

Routes of exposure: Inhalation
Remarks: No data available
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

Version: 8.0  Revision Date: 04/24/2019  SDS Number: 67748-00015  Date of last issue: 02/07/2019  Date of first issue: 02/27/2015

Imipenem:
Remarks: May cause sensitization of susceptible persons by inhalation of aerosol or dust.
Routes of exposure: Skin contact
Remarks: Not classified due to lack of data.

Relebactam:
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Dermal
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Sodium hydrogen [R-[R*,S*(Z)]-7-[(2-amino-2-carboxylatoethyl)thio]-2-[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate:
Genotoxicity in vitro: Test Type: Microbial mutagenesis assay (Ames test) Result: negative

Imipenem:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
Test Type: reverse mutation assay
Result: negative
Test Type: unscheduled DNA synthesis assay
Result: negative
Test Type: Chromosomal aberration
Result: negative
Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo: Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative

Relebactam:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Test Type: Chromosome aberration test in vitro Result: negative
Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

IARC: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP: No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:
Effects on fertility: Test Type: Fertility/early embryonic development
Application Route: Intravenous
Fertility: LOAEL: 1,000
Symptoms: No adverse effects.
Result: No effects on fertility and early embryonic development were detected.

Imipenem:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Intravenous
Fertility: LOAEL: 80 mg/kg body weight
Symptoms: No adverse effects., Reduced fetal weight.
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Subcutaneous
Fertility: LOAEL: 320 mg/kg body weight
Symptoms: No adverse effects., Reduced fetal weight.
Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development: Test Type: Development
### Imipenem / Cilastatin / Relebactam Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue: 02/07/2019</th>
<th>Date of first issue: 02/27/2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.0</td>
<td>04/24/2019</td>
<td>67748-00015</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Species: Monkey
- **Application Route:** Intravenous
- **Developmental Toxicity:** LOAEL: 100 mg/kg body weight
- **Result:** Embryotoxic effects and adverse effects on the offspring were detected.
  - No teratogenic effects.

#### Test Type: Development
- **Species:** Rabbit
- **Application Route:** Intravenous
- **Developmental Toxicity:** NOAEL: 60 mg/kg body weight
- **Result:** No teratogenic effects.

#### Species: Rat
- **Application Route:** Intravenous
- **Developmental Toxicity:** NOAEL: 60 mg/kg body weight
- **Result:** No teratogenic effects.

#### Reproductive toxicity - Assessment:
- Some evidence of adverse effects on development, based on animal experiments.

#### Relebactam:

#### Effects on fertility:
- **Test Type:** Pre-/postnatal development
- **Species:** Rat
- **Application Route:** Subcutaneous
- **Fertility:** NOAEL: 450 mg/kg body weight

#### Effects on fetal development:
- **Test Type:** Embryo-fetal development
- **Species:** Rat
- **Application Route:** Intraperitoneal injection
- **Embryo-fetal toxicity:** NOAEL: 450 mg/kg body weight
  - **Result:** No effects on fetal development.

- **Test Type:** Embryo-fetal development
  - **Species:** Mouse
  - **Application Route:** Intraperitoneal injection
  - **Embryo-fetal toxicity:** NOAEL: 450 mg/kg body weight
  - **Result:** No effects on fetal development.

- **Test Type:** Development
  - **Species:** Rat
  - **Application Route:** Intravenous
  - **Developmental Toxicity:** NOAEL: >= 450 mg/kg body weight
  - **Result:** No effects on fertility and early embryonic development were detected.

- **Test Type:** Development
  - **Species:** Rabbit
  - **Application Route:** Intravenous
  - **Developmental Toxicity:** NOAEL: 450 mg/kg body weight
  - **Result:** No effects on fetal development.
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Kidney) through prolonged or repeated exposure.

Components:

Relebactam:
Target Organs: Kidney
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sodium hydrogen [R-[R*,S*-(Z)]]-7-[(2-amino-2-carboxylatoethyl)thio]-2-[(2,2-
dimethylcyclopropyl)carbonyl]amino]hept-2-enoate:

Species: Rat
NOAEL: >= 500 mg/kg
Application Route: Intravenous
Exposure time: 90 Days
Remarks: No significant adverse effects were reported

Species: Monkey
NOAEL: >= 500 mg/kg
Application Route: Intravenous
Exposure time: 5 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 180 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Species: Rabbit
NOAEL: 150 mg/kg

Imipenem:
Species: Monkey
NOAEL: 60 mg/kg
LOAEL: 150 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Target Organs: Kidney

Species: Monkey
NOAEL: 120 mg/kg
Application Route: Subcutaneous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 180 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported
Imipenem / Cilastatin / Relebactam Formulation

Application Route: Intravenous

Target Organs: Kidney

Relebactam:
Species: Rat, female
NOAEL: 150 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Rat, male
NOAEL: 450 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Monkey
NOAEL: 25 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Monkey
NOAEL: 37.5 mg/kg
Application Route: Intravenous
Exposure time: 30 d

Species: Monkey
NOAEL: 50 mg/kg
LOAEL: 150 mg/kg
Application Route: Intravenous
Exposure time: 3 Months
Target Organs: Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Imipenem:
Inhalation: Symptoms: Nausea, Vomiting, Diarrhea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
Remarks: May cause sensitization of susceptible persons by inhalation of aerosol or dust.

Relebactam:
Skin contact: Symptoms: Pain, Discomfort, Diarrhea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo
SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

**Sodium hydrogen [R-[R*,S*-Z]]-7-[(2-amino-2-carboxyloxyethyl)thio]-2-[[2,2-dimethylcyclopropyl]carbonyl]amino]hept-2-enoate:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 99 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants:**
  - EC50 (Anabaena flos-aquae): > 99 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
  - NOEC (Anabaena flos-aquae (cyanobacterium)): 99 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
- **Toxicity to microorganisms:**
  - EC50: > 1,000 mg/l
    - Exposure time: 3 h
    - Test Type: Respiration inhibition
    - Method: OECD Test Guideline 209

**Imipenem:**
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 78 mg/l
  - Exposure time: 48 h
- **Toxicity to algae/aquatic plants:**
  - EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0058 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
  - NOEC (Anabaena flos-aquae (cyanobacterium)): 0.0025 mg/l
    - Exposure time: 72 h
    - Method: OECD Test Guideline 201
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 74
Imipenem / Cilastatin / Relebactam Formulation

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Relebactam:
Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 2.7 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
NOEC: 96.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:


Biodegradability: Result: rapidly degradable
Biodegradation: 96 %
Exposure time: 23 hrs

Result: Not readily biodegradable.
Biodegradation: 27 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Imipenem:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 29 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Relebactam:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 11.3 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:


Partition coefficient: n-octanol/water:
log Pow: -3.53

Imipenem:

Partition coefficient: n-octanol/water:
log Pow: < -1

Relebactam:

Partition coefficient: n-octanol/water:
log Pow: < -2

Mobility in soil

Components:

Relebactam:
Distribution among environmental compartments: log Koc: 2.3

Other adverse effects:
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods:
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
- Class: 9
- Packing group: III
- Labels: 9

IATA-DGR
- UN/ID No.: UN 3077
- Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Imipenem)
- Class: 9
- Packing group: III
- Labels: Miscellaneous
- Packing instruction (cargo aircraft): 956
- Packing instruction (passenger aircraft): 956
- Environmentally hazardous: yes

IMDG-Code
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
- Class: 9
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F
- Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
**SAFETY DATA SHEET**

**Imipenem / Cilastatin / Relebactam Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.0</td>
<td>04/24/2019</td>
<td>67748-00015</td>
<td>02/07/2019</td>
<td>02/27/2015</td>
</tr>
</tbody>
</table>

**49 CFR**

- **UN/ID/NA number**: UN 3077
- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Imipenem)
- **Class**: 9
- **Packing group**: III
- **Labels**: CLASS 9
- **ERG Code**: 171
- **Marine pollutant**: yes (Imipenem)
- **Remarks**: Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION**

**EPCRA - Emergency Planning and Community Right-to-Know**

**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**

- Combustible dust
- Serious eye damage or eye irritation
- Respiratory or skin sensitization
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)

**SARA 313**

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations**

**Pennsylvania Right To Know**

<table>
<thead>
<tr>
<th>Chemical</th>
<th>CAS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 8.0  Revision Date: 04/24/2019  SDS Number: 67748-00015  Date of last issue: 02/07/2019

The ingredients of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

<table>
<thead>
<tr>
<th>Flammability</th>
<th>Health</th>
<th>Instability</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

- HEALTH: *
- FLAMMABILITY: 3
- PHYSICAL HAZARD: 0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the """" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of
### SAFETY DATA SHEET

**Imipenem / Cilastatin / Relebactam Formula-**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.0</td>
<td>04/24/2019</td>
<td>67748-00015</td>
<td>02/07/2019</td>
<td>02/27/2015</td>
</tr>
</tbody>
</table>

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Sources of key data used to compile the Material Safety Data Sheet:**


**Revision Date:** 04/24/2019

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

**US / Z8**